Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
about
Hormone Replacement Therapy: An Increased Risk of Recurrence and Mortality for Breast Cancer Patients?A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapyUltra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.Managing aromatase inhibitors in breast cancer survivors: not just for oncologistsUrogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy.Urinary symptoms in breast cancer: a systematic review.Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Clinical Pearls in breast diseaseUse of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review.Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients.Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?Prevalence, associated factors, and relationship to quality of life of lower urinary tract symptoms: a cross-sectional, questionnaire survey of cancer patients.Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy.Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.Treatment with oestrogen or manual separation for labial adhesions - initial outcome and long-term follow-up.
P2860
Q26771946-C8ED7196-AA5D-41F3-9D99-86D41B933E8CQ33605919-E6AF6CAB-7557-48B9-9D93-B2A7831D2CEFQ33628455-443B3007-63AB-47A4-B07B-5747E8674CAAQ33884184-88CB558C-FC4A-4C36-BC32-816D5AF4DBFDQ34108946-F77CC24A-A788-4421-99F3-3C671AA4705AQ35354249-B903271D-7988-439F-A5D5-6676EF9041AFQ35640048-8C0B39DF-D50E-4D8A-BA5F-7626DF9A3199Q35824414-76BD7505-4979-438A-9FE0-A028830294E9Q36399021-036560E5-25A3-4623-9B23-94F894DBD9BCQ37611334-2B5AC025-B25D-4EBC-9F9B-2151AB73A70EQ37992713-E4B85D5D-2D9F-4CCD-A590-3233BE62F12DQ39162361-57EE0120-D0A5-465E-B1BE-110625E973CBQ39418034-89BCF2BC-5EE6-445A-BC84-C752E50663A8Q43145015-202CF2EE-5852-44B7-96AE-1AF0C0A06365Q47558942-6E33FBEA-5201-4FED-BDAB-EF6748B15542Q47650581-E224EDB7-E157-4C3F-A44C-C3789E75EACCQ48058845-C30E2096-88AF-4C3B-A6F1-16F42AD334E4Q52666169-758A8E79-1BAA-4710-A23E-0FFDAC6C3D7E
P2860
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
@en
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
@nl
type
label
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
@en
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
@nl
prefLabel
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
@en
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
@nl
P2093
P1433
P1476
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
@en
P2093
Christine Simmons
Mark Clemons
Mateya Trinkaus
Sheray Chin
Wendy Wolfman
P304
P356
10.1634/THEONCOLOGIST.2007-0234
P577
2008-03-01T00:00:00Z